Published in AIDS Weekly, February 5th, 2007
Study 1: Data detailed in "Valproic acid does not affect markers of human immunodeficiency virus disease progression" have been presented. According to recent research from the United States, "Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n=30) examined effects of VPA on markers of HIV progression."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.